You are now leaving ghalsummit.com Content of the website you are visiting is controlled by Bayer AG
Joseph Lin is Vice President and Global Head Hemophilia at Bayer Pharmaceuticals. He was appointed to this role in August 2021, and is based in Basel, Switzerland.
Joe is a seasoned global pharmaceutical commercial leader with over 25 years of experience in operational and strategic marketing roles. Joe joined Bayer in 2014 as VP, Global Launch Team Leader for Jivi, an extended half-life rFVIII replacement treatment, which was successfully launched in 2018, and remains the flagship and key growth brand within Bayer’s hemophilia portfolio. Joe is passionate about serving and innovating for patients, and is particularly excited to help advance Bayer’s aspiration to bring gene therapy to people living with genetic diseases such as hemophilia A.
Prior to joining Bayer, Joe held positions of increasing scope and responsibility across several large pharmaceutical companies, including Pfizer, Johnson & Johnson, and Merck, with experience in a variety of therapeutic/disease areas such as oncology, urology, CNS, virology, and vaccines.
Joe was born and raised in the United States, and, together with his wife and two children, have had the tremendous opportunity to live and work in Europe for the past 6 years. Joe holds a BA in Economics and Neuroscience from the University of Pennsylvania and MBA from Columbia Business School.